Cardiovasc Diabetol 17:62 Correale M, Petroni R, Coiro S, Antohi E-L, Monitillo F, Leone M, Triggiani M, Ishihara S, Dungen H-D, Sarwar CMS, Memo M, Sabbah HN, Metra M, Butler J, Nodari S (in press) Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins
Si bien Ana reconoce que no padeca ni de diabetes ni de otra enfermedad que impacte en su sobrepeso, ella inici a implementar esta medicina en su rutina diaria
1 A 2025 narrative review by Varughese and colleagues describes the broader animal-data picture for GLP-1 receptor agonists: lower fetal weight, delayed bone development, skeletal differences, and abnormalities in internal organs in animals exposed during gestation
However, statistics show that GLP-1 medications used for weight loss are rarely covered
Despite their potential benefits, the risk of psychiatric adverse effects requires cautious administration
Once that feels natural, gradually do a little more as it feels comfortable